Table 1.
Criteria for inclusion and exclusion in the AGENDA trial.
Figure 1.
Flowchart for the AGENDA trial.
Table 2.
Characteristics of participants at entry.
Table 3.
Assessed adverse events by the UKU Side Effect Rating Scale for 78 healthy first degree relatives of patients with a history of major depressive disorder following four weeks of intervention by escitalopram 10 mg (N = 39) or placebo (N = 39) in the AGENDA trial.
Table 4.
The distributions of the primary outcome measure and other characteristics of plasma cortisol and plasma ACTH in the combined DEX-CRH test in 73 healthy first-degree relatives of patients with a history of major depressive disorder, in the escitalopram 10 mg group (N = 38) and the placebo group (N = 35).
Figure 2.
The mean of ln (p-cortisol/unit) versus time in the placebo group (squares) and in the escitalopram group (triangles).
For each of the time intervals [1≤time≤5], [6≤time≤9] and [10≤time≤17] there is an approximate linear relationship between time and mean values.